Lakeshore Biopharma (LSB) Competitors $2.96 +0.26 (+9.63%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends LSB vs. EPRX, RANI, ANIX, ADAG, ASRT, PWUP, CTMX, ME, ANL, and KPTIShould you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include Eupraxia Pharmaceuticals (EPRX), Rani Therapeutics (RANI), Anixa Biosciences (ANIX), Adagene (ADAG), Assertio (ASRT), PowerUp Acquisition (PWUP), CytomX Therapeutics (CTMX), 23andMe (ME), Adlai Nortye (ANL), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry. Lakeshore Biopharma vs. Eupraxia Pharmaceuticals Rani Therapeutics Anixa Biosciences Adagene Assertio PowerUp Acquisition CytomX Therapeutics 23andMe Adlai Nortye Karyopharm Therapeutics Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts rate EPRX or LSB? Eupraxia Pharmaceuticals presently has a consensus target price of $9.00, indicating a potential upside of 201.00%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is EPRX or LSB more profitable? Lakeshore Biopharma's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Lakeshore Biopharma N/A N/A N/A Does the media refer more to EPRX or LSB? In the previous week, Lakeshore Biopharma had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Lakeshore Biopharma and 1 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.00 equaled Lakeshore Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lakeshore Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, EPRX or LSB? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.72-4.15Lakeshore Biopharma$573.42M0.05-$61.09MN/AN/A Do institutionals and insiders believe in EPRX or LSB? 52.6% of Lakeshore Biopharma shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in EPRX or LSB? Eupraxia Pharmaceuticals received 3 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesLakeshore BiopharmaN/AN/A SummaryEupraxia Pharmaceuticals beats Lakeshore Biopharma on 6 of the 11 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Lakeshore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeshore BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.55M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E RatioN/A10.5991.3417.19Price / Sales0.05195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book0.335.104.794.78Net Income-$61.09M$151.51M$120.07M$225.60M7 Day Performance18.64%-2.15%-1.89%-1.24%1 Month Performance15.18%-3.14%11.45%3.36%1 Year PerformanceN/A11.50%30.61%16.58% Lakeshore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeshore Biopharma0.4996 of 5 stars$2.96+9.6%N/AN/A$27.55M$573.42M0.00773News CoverageGap UpHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.2141 of 5 stars$3.41-0.9%$9.00+163.9%N/A$93.03MN/A-4.7829Positive NewsRANIRani Therapeutics3.4495 of 5 stars$1.61-3.0%$11.71+627.6%-55.1%$92.24M$2.72M-1.57110Positive NewsANIXAnixa Biosciences2.9585 of 5 stars$2.83-0.7%$8.50+200.4%-28.8%$91.07M$210,000.00-7.315ADAGAdagene2.0012 of 5 stars$2.02-1.9%$5.00+147.5%+13.9%$89.43M$815,746.000.00260ASRTAssertio3.3731 of 5 stars$0.93+1.5%$3.25+248.0%-14.8%$89.16M$125.76M-1.3020Gap DownPWUPPowerUp AcquisitionN/A$11.43flatN/A+5.7%$88.81MN/A0.00N/ACTMXCytomX Therapeutics4.3209 of 5 stars$1.12+0.9%$5.77+415.4%-18.7%$87.65M$101.21M6.53170News CoveragePositive NewsME23andMe2.38 of 5 stars$3.35flat$9.40+180.6%-81.5%$87.50M$219.64M-0.13770Positive NewsANLAdlai Nortye1.5882 of 5 stars$2.36+3.1%$9.00+281.4%-75.7%$87.08M$5M0.00127KPTIKaryopharm Therapeutics3.8062 of 5 stars$0.67-4.3%$5.00+646.4%-16.2%$84.54M$148.44M-0.61380 Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Competitors Rani Therapeutics Competitors Anixa Biosciences Competitors Adagene Competitors Assertio Competitors PowerUp Acquisition Competitors CytomX Therapeutics Competitors 23andMe Competitors Adlai Nortye Competitors Karyopharm Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LSB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
